Canadian Cancer Trials Group - Tumour Bank
Logged in as: Public
Location: Home - Disease Sites - - CO14
CO14 Details
Status: Closed 
Activation Date: 1999OCT12
Closing Date: 2002MAY31
Phase: III 

Description: Phase III Randomized Study of Adjuvant Immunotherapy with Monoclonal Antibody 17-1A Versus No Adjuvant Therapy Following Resection for Stage II (Modified Astler-Coller B2) Adenocarcinoma of the Colon 

Eligibility: Pathologically documented Stage II pT3N0 or pT4bN0 (Modified Astler-Coller B2) colon adenocarcinoma. Complete, en bloc resection of all of the primary tumour, performed as an open procedure and not laparoscopically or laparoscopically assisted. No evidence of perforation or clinical obstruction of the bowel. The gross distal margin of the primary tumour must lie above the peritoneal reflection (i.e. it must be a colon, not a rectal cancer). No previous radiation or chemotherapy for this malignancy. Age > 18 years. CALGB performance status 0 - 1. No current corticosteroid therapy for any reason. No prior exposure to murine antibodies. No uncontrolled or severe cardiovascular disease. No history of pancreatitis. Non-pregnant and non-lactating. No previous or concurrent malignancy. 

Objective: To determine whether adjuvant treatment with MoAb 17-A will improve the probability of overall and disease-free survival, and increase disease-free intervals in patients who have undergone resection of a stage II (pT3N0 or pT4bN0) colon cancer. To evaluate a panel of prognostic markers, in order to correlate these measures with survival and recurrence after adjuvant therapy in patients who have undergone resection of a Stage II (pT3N0 or pT4bN0) colon cancer. 

Participation: Open to member centres 

Lay Description: The purpose of this study is to compare the effects (good and bad) of an experimental drug called Monoclonal Antibody 17-1A (or MoAb17-1A) to standard care (which is no treatment and careful observation) to see which is better. MoAb17-1A is unlike chemotherapy drugs commonly used to treat cancer because MoAb17-1A can attack cancer or tumor cells in a way different than these chemotherapy drugs. 

Primary Publication Show

Other Publications Show

Inventory
Hide Tissue Samples
Disease Site Trial Code Patients Accrued Patients - Blocks Patients - Slides Patients - Blocks and/or Slides
GASTRO-INTESTINAL CO14 160 37 57 90
Hide TMA Samples
(Core size is 0.6 mm)
Disease Site Trial Code Patients Accrued TMA Blocks Patients on TMA Blocks
GASTRO-INTESTINAL CO14 160 0 0
Hide Fluid Samples
Disease Site Trial Code Patients Accrued Patients - Whole Blood Patients - Cellular Component of Blood Patients - DNA extracted from Blood Patients - RNA extracted from Blood Patients - Plasma Patients - Serum Patients - Urine Patients - Buccal
GASTRO-INTESTINAL CO14 160 0 0 0 0 0 0 0 0